- Home
- ATHA vs KLXE Comparison
ATHA vs KLXE Comparison
Compare ATHA & KLXE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- KLXE
- Stock Information
- Founded
- ATHA 2011
- KLXE 2018
- Country
- ATHA United States
- KLXE United States
- Employees
- ATHA N/A
- KLXE N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- KLXE Oilfield Services/Equipment
- Sector
- ATHA Health Care
- KLXE Energy
- Exchange
- ATHA Nasdaq
- KLXE Nasdaq
- Market Cap
- ATHA 93.5M
- KLXE 90.4M
- IPO Year
- ATHA 2020
- KLXE N/A
- Fundamental
- Price
- ATHA $0.67
- KLXE $5.42
- Analyst Decision
- ATHA Buy
- KLXE Hold
- Analyst Count
- ATHA 4
- KLXE 1
- Target Price
- ATHA $11.25
- KLXE $4.50
- AVG Volume (30 Days)
- ATHA 14.2M
- KLXE 120.5K
- Earning Date
- ATHA 11-07-2024
- KLXE 10-31-2024
- Dividend Yield
- ATHA N/A
- KLXE N/A
- EPS Growth
- ATHA N/A
- KLXE N/A
- EPS
- ATHA N/A
- KLXE N/A
- Revenue
- ATHA N/A
- KLXE $738,000,000.00
- Revenue This Year
- ATHA N/A
- KLXE N/A
- Revenue Next Year
- ATHA N/A
- KLXE $4.79
- P/E Ratio
- ATHA N/A
- KLXE N/A
- Revenue Growth
- ATHA N/A
- KLXE N/A
- 52 Week Low
- ATHA $0.41
- KLXE $4.18
- 52 Week High
- ATHA $4.30
- KLXE $12.13
- Technical
- Relative Strength Index (RSI)
- ATHA 51.78
- KLXE 57.97
- Support Level
- ATHA $0.60
- KLXE $5.47
- Resistance Level
- ATHA $0.83
- KLXE $6.33
- Average True Range (ATR)
- ATHA 0.10
- KLXE 0.40
- MACD
- ATHA 0.03
- KLXE 0.16
- Stochastic Oscillator
- ATHA 61.60
- KLXE 71.83
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.